GlassScriptPhysician profile
Anthony R Rooklin
NPI 1013008333
$319,163.89
in general payments reported to CMS, 2019-2025
45 companies · $48K in 2025
The $48K reported for 2025 was more than what 96% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90K · 2020: $27K · 2021: $31K · 2022: $37K · 2023: $34K · 2024: $52K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $110K · Food and Beverage: $12K · Travel and Lodging: $6,445 · Consulting Fee: $6,153 · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $109,805.00 |
| Food and Beverage | $11,504.15 |
| Travel and Lodging | $6,445.48 |
| Consulting Fee | $6,152.74 |
| Education | $248.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $177,334.25 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Novartis Pharmaceuticals Corporation | $67,599.98 | 2019-2025 | |
| Pfizer INC. | $20,235.14 | 2019-2025 | |
| Genentech USA, INC. | $15,552.40 | 2019-2025 | Xolair |
| Glaxosmithkline, LLC. | $11,935.10 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Optinose US, INC. | $11,006.05 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $6,629.28 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Shire North American Group INC | $1,519.12 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $1,351.37 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,276.20 | 2019-2025 | |
| Abbvie INC. | $864.40 | 2021-2024 | Rinvoq |
| Csl Behring | $562.53 | 2019-2025 | Andembry, Hizentra, Haegarda |
| Grifols USA, LLC | $414.15 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Amgen INC. | $402.89 | 2022-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $359.46 | 2021-2024 | Orladeyo |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Rooklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.